Article
Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2000
Houghton P J, Stewart C F, Cheshire P J, Richmond L B, Kirstein M N, Poquette C A, Tan M, Friedman H S, Brent T P
Abstract excerpt
The activity of temozolomide combined with irinotecan (CPT-11) was evaluated against eight independent xenografts (four neuroblastomas, three rhabdomyosarcomas, and one glioblastoma). In all studies, temozolomide was administered p.o. daily for 5 consecutive days/cycle, found in preliminary studies to be the optimal schedule for administration. Irinotecan was administered i.v. for 5 days for 2 consecutive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.